GlassScriptPhysician profile
Fadi W Alkhankan
NPI 1639383664
$5,479.09
in general payments reported to CMS, 2019-2025
28 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $92.02 · 2021: $262 · 2022: $2,204 · 2023: $1,100 · 2024: $681 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.08 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,351.72 | 2022-2023 | Monarch Platform |
| Glaxosmithkline, LLC. | $1,032.06 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $676.54 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.60 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Insmed, INC. | $272.74 | 2021-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $235.77 | 2023-2024 | Wakix |
| Mylan Specialty L.P. | $172.85 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $152.77 | 2023-2024 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $134.28 | 2022-2023 | Opsumit, Uptravi |
| Electromed, INC. | $129.06 | 2021-2025 | Smartvest |
| Genzyme Corporation | $119.18 | 2021-2025 | |
| United Therapeutics Corporation | $91.15 | 2022-2024 | Tyvaso |
| Amgen INC. | $81.31 | 2022-2023 | Tezspire |
| Pulmonx Corporation | $77.71 | 2021-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Baxter Healthcare | $69.39 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $67.69 | 2025 | Ohtuvayre |
| Philips North America LLC | $61.03 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.79 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $44.42 | 2023-2024 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $41.68 | 2024-2025 | Purified Cortrophin Gel |
| Resmed Corp | $39.25 | 2024-2025 | |
| Covis Pharma Gmbh | $35.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.61 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $17.96 | 2024 | Keytruda |
| Lilly USA, LLC | $15.89 | 2025 | |
| Viatris Specialty LLC | $15.35 | 2025 | Yupelri |
| Abbvie INC. | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Alkhankan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.